Fulcrum Therapeutics vs Keros Therapeutics
FULC and KROS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FULC and KROS compare
Fulcrum Therapeutics is the larger company, worth 1.4 times as much as Keros Therapeutics ($288M against $204M).
Keros Therapeutics scores higher on the StockData Score (9 against 8 for Fulcrum Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FULC | KROS |
|---|---|---|
| Size and price | ||
| Market cap | $288M | $204M |
| Share price | $3.77 | $10.30 |
| Change, 1 year | −54.9% | −41.0% |
| Change, 5 years | −78.0% | −82.8% |
| Beta (5Y) | 1.56 | 1.11 |
| Employees | 55 | 78 |
| StockData Score | ||
| Total score | 8 | 9 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 5.1× |
| P/B | 1.0× | 0.7× (better) |
| FCF yield | −22.7% (better) | −23.6% |
| Fair value | – | $24.09 |
| Margin of safety | – | 57.3% |
| Growth | ||
| Revenue growth (TTM) | – | −83.4% |
| Net income growth (TTM) | – | −196% |
| EPS growth (TTM) | – | −282% |
| Profitability | ||
| Operating margin | – | −181% |
| Net margin | – | −153% |
| FCF margin | – | −119% |
| Return on equity | −30.5% | −12.6% (better) |
| Return on invested capital | −41.3% (better) | −389% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 36.19 (better) | 18.14 |
| Altman Z-score | 16.95 (better) | 2.37 |
| Piotroski F-score | 3 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | −1.5% | – |
| Shareholder yield | −1.5% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 112% | 101% |
| Held by insiders | 34.7% | 53.3% |
| Insider net buying, 12 months | −$57.5M | −$447K (better) |
| Short interest, % of float | 12.9% | 11.7% |
Go deeper
- FULC stock overview
- FULC income statement
- FULC valuation and score
- KROS stock overview
- KROS income statement
- KROS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.